Sanofi's High-Dose Flu Vaccine Shows Enhanced Protection for Seniors

Sanofi's Efluelda, known as Fluzone High-Dose in North America, proves superior in reducing influenza-related hospitalizations in adults 65 and older compared to standard-dose vaccines. The FLUNITY-HD study, published in The Lancet, highlights a 31.9% reduction in lab-confirmed flu hospitalizations.

The study, involving nearly half a million participants, also shows Efluelda provides 8.8% more protection against pneumonia/influenza hospitalizations and reduces cardio-respiratory hospitalizations by 6.3%. Conducted across multiple seasons, it is the largest study of its kind.

This evidence supports the vaccine's efficacy in vulnerable populations, potentially influencing public health strategies. For every 515 seniors vaccinated with Efluelda, one all-cause hospitalization is prevented, helping mitigate healthcare costs.